Novel immuno– and stem cell–based therapies
Vladka, Čurin Šerbec
The main areas of the research at the Blood Transfusion Center of Slovenia are cell therapies, stem cells and new diagnostic reagents, based on monoclonal antibodies (mAbs). Our laboratories are equipped for cell-culture work (certified GLP; GMP in reconstruction), molecular biology, immunological techniques and biochemistry. In the course of our research we conducted studies and applied projects (the last mainly industrial) beside production of reagents, with common topic - the antibodies. They were prepared and used to optimise and validate ELISA tests for quality control assessment of the end-product (polyclonal antibodies, in production of drugs), to study protein structure, for immunodiagnostics and as potential immunotherapeutics. Among different mAbs, which we produced in the last decade, a panel of mAbs against prion protein (PrP) and mAbs against bilitranslocase (prepared in collaboration with the University of Trieste) will be studied with different project partners in the scope of Trans2Care. We are fully dedicated to translate the results of the basic research onto applied, possibly clinical level and to contribute to improved healthcare in a sense of advanced modes of immunotherapeutics development and cell based therapies.
EUT Edizioni Università di Trieste
Sendi Montanič, Uroš Rajčevič and Vladka Čurin Šerbec, Novel immuno– and stem cell–based therapies, in Sabina Passamonti (ed.), The Partners and the Objectives of Trans2Care, an Italy-Slovenia cross-border network of science and healthcare institutions, EUT - Edizioni Università di Trieste, 2014, pp. 93-97